

# PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Pediatric Autonomic Disorders**

Felicia B. Axelrod, Gisela G. Chelimsky and Debra E. Weese-Mayer

*Pediatrics* 2006;118:309-321

DOI: 10.1542/peds.2005-3032

**This information is current as of October 16, 2006**

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://www.pediatrics.org/cgi/content/full/118/1/309>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2006 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



Editor's Note

*The Journal is interested in receiving for review short articles (1000 words) summarizing recent advances which have been made in the past 2 or 3 years in specialized areas of research and patient care.*

## Pediatric Autonomic Disorders

Felicia B. Axelrod, MD<sup>a</sup>, Gisela G. Chelimsky, MD<sup>b</sup>, Debra E. Weese-Mayer, MD<sup>c</sup>

<sup>a</sup>Department of Pediatrics and Neurology, New York University School of Medicine, New York, New York; <sup>b</sup>Department of Pediatrics, Case Western Reserve School of Medicine, Cleveland, Ohio; <sup>c</sup>Department of Pediatrics, Rush University School of Medicine, Chicago, Illinois

The authors have indicated they have no financial relationships relevant to this article to disclose.

### ABSTRACT

The scope of pediatric autonomic disorders is not well recognized. The goal of this review is to increase awareness of the expanding spectrum of pediatric autonomic disorders by providing an overview of the autonomic nervous system, including the roles of its various components and its pervasive influence, as well as its intimate relationship with sensory function. To illustrate further the breadth and complexities of autonomic dysfunction, some pediatric disorders are described, concentrating on those that present at birth or appear in early childhood.

[www.pediatrics.org/cgi/doi/10.1542/peds.2005-3032](http://www.pediatrics.org/cgi/doi/10.1542/peds.2005-3032)

doi:10.1542/peds.2005-3032

#### Key Words

autonomic nervous system, cardiovascular, sympathetic nervous system, parasympathetic nervous system, viscerosensory

#### Abbreviations

FD—familial dysautonomia  
ANS—autonomic nervous system  
CAN—central autonomic network  
PHOX2B—paired-like homeobox 2B  
NGF—nerve growth factor  
CFS—chronic fatigue syndrome  
HSAN—hereditary sensory and autonomic neuropathy  
CIPA—congenital insensitivity to pain with anhidrosis  
CCHS—congenital central hypoventilation syndrome  
CVS—cyclic vomiting syndrome  
POTS—postural orthostatic tachycardia

Accepted for publication Feb 13, 2006

Address correspondence to Felicia B. Axelrod, MD, Dysautonomia Treatment and Evaluation Center, New York University School of Medicine, 530 First Ave, Suite 9Q, New York, NY 10016. E-mail: felicia.axelrod@med.nyu.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2006 by the American Academy of Pediatrics

**A**PPRECIATION OF THE breadth of autonomic disorders has increased since Langley<sup>1</sup> originally proposed the generic term “autonomic nervous system” (ANS) and designated its division into the sympathetic, parasympathetic, and enteric nervous systems. Although a number of texts dedicated to various aspects of autonomic function now are available,<sup>2-4</sup> they tend to concentrate on adult disorders, with pediatric autonomic disorders poorly represented. Even within the first text dedicated to describing various clinical disorders by Dancis,<sup>5</sup> the only pediatric disorder included was familial dysautonomia (FD). Now, more than 20 years later, investigators are beginning to appreciate the value of genetic autonomic disorders as models to advance the understanding of pathophysiologic mechanisms involved in autonomic dysfunction.<sup>6,7</sup> In fact, the original description of FD in 1949<sup>8</sup> preceded the description by Shy and Drager<sup>9</sup> of the adult neurodegenerative syndrome characterized by central autonomic dysfunction by 11 years. Although the report by Shy and Drager initiated expansion of autonomic research and eventual founding of an autonomic subsection within neurology and autonomic societies in the United States and Europe, the same level of interest has not been seen within the pediatric community. Perhaps this disparity has evolved through lack of awareness of the myriad of pediatric autonomic disorders or inadequate residency education regarding evaluation of this particular system.

The ANS is pervasive and integrates multiple secondary functions so that symptoms can be widespread and confounding. In addition, there are often associated sensory perturbations, because the development and maintenance of the autonomic and sensory systems are closely linked. The goal of this article is to increase awareness of the expanding spectrum of pediatric autonomic disorders so that this population can benefit from the advances being made in evaluation and treatment.<sup>2,3</sup> We provide an overview of the ANS and stress the extent of its influence, discuss the protean symptoms and manifestations caused by autonomic perturbations, and emphasize the expanding number of pediatric disorders that feature autonomic dysfunction.

## THE ANATOMY AND PHYSIOLOGY OF THE ANS

### General Description

The ANS is a visceral and largely involuntary motor/effector system that is traditionally divided into sympathetic (thoracolumbar) and parasympathetic (craniosacral) divisions, each with a central and a peripheral component.<sup>10</sup> In addition, there is an important enteric division. Outflow can occur independently, but to some extent it is regulated and integrated by the central autonomic network (CAN).<sup>11</sup> The CAN maintains integral relationships with visceral sensory neurons via afferent input from the vagus nerve and relays transmission

through the nucleus tractus solitarius to the hypothalamus, amygdala, and forebrain.<sup>11</sup>

### Embryologic Development

Development of the ANS is intimately related to the development of the sensory nervous system; both have their embryonic origins in the multipotential neural crest cells. These cells migrate and eventually evolve into sensory and autonomic ganglia as well as the adrenal chromaffin cells. Their differentiation and commitment to function in the mature nervous system is incumbent on exposure to growth factors released by structures along the migratory route and then within the target tissue. Eventually, specificity will be determined by their ability to produce specific neurotransmitters. Therefore, one could postulate that an early genetic error affecting initial migration would cause profound decreases in both sensory and autonomic populations, whereas a later genetic error might only affect cell survival to one or both populations, causing more erratic and varied clinical expression.

### Growth Factors and Neurotransmitters

Various factors promote normal progression from the embryonic to the mature autonomic and sensory nervous systems.<sup>12,13</sup> Several key transcription factors have been identified that play critical roles in the development of the ANS, such as the *MASH1* (mammalian achaete-scute homologue) and *PHOX* (paired-like homeobox) 2B genes, which are necessary for differentiation of uncommitted neural crest cells to the developing ANS.<sup>14,15</sup> Another important regulator of development and survival is nerve growth factor (NGF).<sup>16,17</sup> In the embryonic neuron, NGF binding promotes migration from the neural crest and enhances maturation through neurite outgrowth. In the mature neuron, dependence on NGF decreases, but it continues to enhance neurotransmitter synthesis.<sup>17</sup>

The peripheral ANS provides physiologic responses that are critical for homeostasis and acute adaptations to stressful circumstances via multiple transmitters and a chemical coding system of autonomic neurons. During the last 2 decades it has become clear that within a single neuron multiple transmitter systems coexist and that within a given ganglion the variety and pattern of neurotransmitters is extensive. In turn, multiple organ systems then respond to the neurotransmitters released via various receptor systems. For both the sympathetic and parasympathetic systems, the preganglionic innervation is largely cholinergic, with terminals releasing acetylcholine at the ganglion synapses. For the sympathetic system, norepinephrine is the major neurotransmitter, but other postganglionic neurotransmitters are also important, among which are substance P, dopamine, and vasoactive intestinal polypeptide. Although the traditional concept is that the sympathetic and parasympathetic

systems are antagonistic, that is not always the case (as indicated in Table 1). Thus, when the sympathetic system is stimulated, a host of receptor systems are activated, including dilation of the pupil, increase in glandular secretions, bronchodilation, increase in heart rate and force of contraction, decrease in gastrointestinal tract motility, decrease in function of the reproductive organs, and mobilization of energy substrates. The parasympathetic system tends to have more focal responses, but some effects may be quite broad, particularly with the wide-ranging innervation of the vagus nerve. However, the parasympathetic system seems to have less influence on exocrine and endocrine function.

### INTEGRATION OF THE PERIPHERAL AND CENTRAL AUTONOMIC NERVOUS SYSTEMS

The varied functions of the peripheral ANS are integrated and regulated by the CAN, the extensive circuitry of which ranges from the forebrain to the brainstem (Table 2).<sup>11</sup> Disorders in the forebrain circuits, such as ischemia secondary to blood-flow disturbance or seizures, can cause cardiac arrhythmia.<sup>18</sup> Within this circuitry, the nucleus tractus solitarius in the medulla oblongata, which receives input from the vagus and glossopharyngeal nerves, functions as a major relay station, allowing continuous feedback and integration. The hypothalamic area seems to have major influences on thermoregulation and sleep/wake cycling. Thus, the CAN serves many critical functions and affects visceromotor and neuroendocrine function as well as motor and pain modulation. It aids in reflex adjustments of autonomic responses and integrates autonomic, neuroendocrine, and behavioral responses that, in turn, maintain homeostasis, emotional expression, and response to stress.<sup>19</sup>

TABLE 1 ANS Functions

Organ	Sympathetic Nervous System	Parasympathetic Nervous System
Eye		
Pupil	Dilatation	Constriction
Ciliary muscle	Relax (far vision)	Constrict (near vision)
Lacrimal gland	Slight secretion	Secretion
Salivary glands	Slight secretion	Secretion
Heart	Increased rate	Decreased rate
	Positive inotropism	Negative inotropism
Lungs	Bronchodilation	Bronchodilation
Gastrointestinal	Decreased motility	Increased motility
Kidney	Decreased output	None
Bladder	Relax detrusor	Contract detrusor
	Contract sphincter	Relax sphincter
Penis	Ejaculation	Erection
Sweat glands	Secretion	Palmar sweating
Blood vessels		
Arterioles	Constriction	None
Muscles		
Arterioles	Constriction or dilatation	None
Metabolism	Glycogenolysis	None

### SYMPTOMS OF AUTONOMIC DYSFUNCTION IN THE PEDIATRIC PATIENT

Because the ANS and its CAN component have pervasive effects that affect multiple other systems secondarily, clinical manifestations can be extremely varied. Rather than use an anatomic approach, one can use a functional or system approach, as listed in Table 3. For this review, only those autonomic disorders with multi-system involvement are considered. Although children with gastroesophageal reflux or asthma have obvious autonomic dysfunction, their care is best relegated to the appropriate subspecialist. However, when more than one system is perturbed, then one might consider that the patient is affected with a more global autonomic disorder. At that point, the differential diagnosis expands and starts to include a number of autonomic disorders that can be considered on the basis of age at presentation.

### PEDIATRIC AUTONOMIC DISORDERS

Many pediatric autonomic disorders are apparent at birth or within the first year of life. Some of these disorders occur as a result of developmental abnormalities caused by specific genetic mutations required for neural crest cell migration and maturation; others occur as a result of prematurity or generalized central dysfunction (Table 4). Those disorders that occur as a result of biochemical errors causing neurotransmitter deficiencies or inefficient mitochondrial metabolism can be more insidious and later in their presentation. In addition, autonomic dysfunction has been noted with various disorders for which mechanisms remain obscure, such as autism and chronic fatigue syndrome (CFS), and also may be associated with various chronic diseases. Table 4 lists some of these disorders, but the list continues to expand. A few representative disorders will be described.

#### Autonomic Disorders Associated With Developmental Arrest or Aberrant Development of Function

##### *Hereditary Sensory and Autonomic Neuropathies*

##### *General Description*

The complexities of the ANS and its intimate relationship with sensory function is especially well illustrated in the group of genetic disorders known as hereditary sensory and autonomic neuropathies (HSANs).<sup>6,7,20</sup> Each HSAN disorder is probably caused by different genetic errors affecting a specific aspect of small fiber neurodevelopment and resulting in variable phenotypic expression.<sup>6,7,20</sup> With the exception of hereditary sensory radicular neuropathy (HSAN type I), which is a dominant disorder presenting in the second decade of life, the other HSANs are autosomal recessive disorders that present at birth. Two HSANs with specific genetic mutations are FD (HSAN type III) and congenital insens-

**TABLE 2 CAN: Anatomy and Function**

Anatomic Area	General Function	Clinical Manifestations
Insular and medial prefrontal cortices	High-order autonomic control: input from gastric mechanoreceptors, arterial chemoreceptors, baroreceptors	Cardiac arrhythmia
Extended amygdala	Autonomic expression of emotional states: integrates autonomic and motor responses	Viscerosensory phenomena (eg, unilateral hyperhidrosis) Vomiting (left temporal focus) Sexual arousal
Hypothalamus	Homeostasis: initiates and coordinates biological rhythms, autonomic, neuroendocrine, and behavioral responses	Hypothermia or hyperthermia  Poor stress response (autonomic storm) Insomnia
Midbrain	Coordinates autonomic, pain-controlling, and motor mechanisms for stress-related, aggressive, and reproductive behaviors	Hypertension or hypotension, arrhythmias  Intractable vomiting and dysmotility Hypoventilation Urinary retention
Pons	Relays viscerosensory information to forebrain	
Nucleus of the tractus solitarius	Relays viscerosensory information from vagus and glossopharyngeal nerves to other CAN regions	
Medulla	Cardiovascular and respiratory control via premotor autonomic and respiratory neurons controlling input to spinal, respiratory, and preganglionic motor neurons	Sleep-disordered breathing (eg, apnea, alveolar hypoventilation)

tivity to pain with anhidrosis (CIPA or HSAN type IV). For each HSAN type, penetrance is complete, but there can be marked variability in expression. Characteristic to all HSANs is that intradermal injection of histamine phosphate fails to elicit a normal axon-flare response.<sup>7</sup> However, FD is the only HSAN for which there is commercially available genetic testing.

#### FD

In FD, the gene is *IKBKAP* (IκB kinase–associated protein gene), and >99% of individuals with FD are homozygous for a mutation in intron 20 that causes a drastic reduction in correctly spliced messenger RNA in neuronal tissue and, therefore, a lack of expression of the normal protein product IKAP (IκB kinase–associated protein).<sup>21,22</sup> It has been postulated that IKAP aids in expression of various neurotransmitters and that production of the abnormal gene product impedes this ability.<sup>23</sup> Although FD is almost exclusive to individuals of Eastern European Jewish extraction,<sup>21,22,24</sup> it is the most prevalent HSAN type and often used as the prototype with which to compare other HSAN disorders.<sup>7</sup> In FD there is inadequate development, as well as limited survival, of sensory and autonomic neurons, with the sympathetic population more widely affected than the parasympathetic population. Pathologic studies have demonstrated decreased unmyelinated and small myelinated neuronal populations in the peripheral sensory nervous system and the ANS. Although central autonomic symptoms are present, no consistent central neuropathology has yet been described.

Although patients with FD have decreased pain and

temperature perception, the sensory perturbations are not as profound as in the other HSANs.<sup>25</sup> Bone and skin pain are diminished but not absent; sensitivity to visceral pain is intact. Corneal and tendon reflexes are hypoactive, and taste appreciation is diminished, consistent with absence of lingual fungiform papillae. With age, vibratory sensory loss and impaired coordination appear.<sup>26</sup>

The autonomic disturbances, however, are very prominent, involve peripheral and central tracts, and impose the greatest impediments to function, especially in the neonatal period.<sup>7,27</sup> In addition to absence of tears (alacrima) with emotional crying, a cardinal feature of the disorder, feeding difficulties resulting from poor oral coordination and hypotonia are frequent. Recurrent misdirection, especially of liquids, and frequent gastroesophageal reflux put the patient at risk for aspiration and chronic lung disease. Protracted episodes of nausea and vomiting can be triggered by emotional or physical stress or even arousal from sleep. These episodes, also termed the dysautonomic crisis, are usually associated with a constellation of signs including agitation, tachycardia, and hypertension. Vasomotor and cardiovascular perturbations manifest as erythematous skin blotching and hyperhidrosis with excitation or even eating. Patients can exhibit both extreme hypertension and profound and rapid postural hypotension without compensatory tachycardia.<sup>7</sup> Supersensitivity to cholinergic and adrenergic agents has been demonstrated.<sup>28,29</sup> Patients have relative insensitivity to hypoxemia,<sup>30–33</sup> which limits their ability to cope with pneumonia or travel to high

**TABLE 3 Functional Organization of Symptoms Associated With ANS Disorders**

System	Dysfunction	Symptom
Vasomotor/cardiovascular	Hypertension	Headache
	Hypotension	Dizziness, lightheadedness
	Arrhythmia	Loss of consciousness/syncope
	Vascular irritability	Acrocyanosis, cold hands and feet, blotching
Gastrointestinal	Oropharyngeal dysmotility	Feeding problems (poor suck, drooling, aspiration pneumonia)
	Esophageal dysmotility	Dysphagia (difficulty swallowing)
	Gastroesophageal reflux	Nausea
	Bowel dysmotility	Recurrent vomiting Bloating Profound constipation or diarrhea
Ophthalmologic	Alacrima	Dry eye
	Nonreactive/sluggish pupils	Dark/light intolerance
	Anisocoria	Severe myopia
	Ptosis	Strabismus
Respiratory	Alveolar hypoventilation	Cyanosis with sleep
	Apnea	Breath-holding spells
	Insensitivity to hypoxia	Syncope at high altitudes/plane travel
	Insensitivity to hypercarbia	
Sudomotor	Altered sweating	Hypohidrosis or hyperhidrosis
	Thermoregulatory abnormalities	Decreased basal body temperature Excessively dry skin Unexplained high fevers
		Sensory defensiveness
		Decreased response to injury, injections, and dental procedures
Neurologic		Self-mutilation
		Insomnia
Urologic	Sleep/wake disturbance	Nocturnal enuresis (>5 years of age)
Psychological	Delayed bladder emptying	Poor socialization skills
	Altered affect	Increased anxiety
	Unusual emotional responses	Poor school performance
	Poor executive planning	Emotional lability
	Learning disability	Tics/phobias
	Attention problems	

altitudes. Ensuing hypoxemia may lead to hypotension, bradyarrhythmia, and even syncope. Developmental milestones are commonly delayed, but intelligence is usually within normal ranges.<sup>34</sup>

Although the gene has been identified, the mainstay of treatment remains preventative and supportive. These treatments have included measures to maintain eye moisture, fundoplication with gastrostomy to provide nutrition and avoid risk of aspiration, use of central agents such as benzodiazepines and clonidine to control vomiting and the dysautonomic crisis, and fludrocortisone and midodrine to combat cardiovascular lability.<sup>7,27</sup> As a result of improved supportive measures, approximately half of these patients now reach adulthood.<sup>35</sup>

#### CIPA

CIPA is caused by mutations in the neurotrophic tyrosine kinase receptor type 1 (*NTRK1*) gene located on chromosome 1 (1q21-q22).<sup>36,37</sup> As a result of loss-of-function mutations, signal transduction at the NGF receptor is impeded and NGF-dependent neurons, the small sensory and sympathetic neurons, fail to survive.

There is no particular ethnic distribution for this disorder, but one half of the reported cases have occurred in consanguineous marriages.<sup>6,7</sup>

CIPA/HSAN type IV is characterized by anhidrosis (absent or markedly decreased sweating),<sup>6</sup> which is probably secondary to impaired thoracolumbar sympathetic outflow. It is the anhidrosis that causes episodic fevers and extreme hyperpyrexia that is usually the earliest sign of the disorder. Anhidrosis also contributes to the thick and calloused appearance of the skin with lichenification of palms, dystrophic nails, and areas of hypotrichosis on the scalp.<sup>38</sup> As evidence of parasympathetic dysfunction, patients exhibit miosis with dilute intraocular mecholyl and have mild postural hypotension. In contrast to patients with FD, emotional tearing is normal, there is no acrocyanosis, and cardiovascular responses are normal in the early years. Gastrointestinal dysmotility is infrequent; vomiting is not a feature of the disease, and cyclical crises do not occur. Insensitivity to hypoxia and hypercapnia has not been noted.

The insensitivity to pain is profound and can result in self-mutilation, autoamputation, and corneal scarring.

**TABLE 4 Pediatric Autonomic Disorders**

Etiology	Classification	Disorders	Gene
Developmental disorders	Hereditary sensory and autonomic disorders	FD (HSAN type III)	IKBKAP
		CIPA (HSAN type IV)	<i>NTRK1</i>
		Congenital sensory neuropathy (HSAN type II)	Unknown
	Allgrove syndrome Cardiorespiratory dysregulation disorders	CCHS	AAAS
		Long-QT syndrome	<i>PHOX2B</i>
			6 genes ( <i>KCNQ1, KVLQT1, HERG, SCN5A, KCNE1, MiRP1</i> )
	Chromosomal disorders	Prader-Willi syndrome	? gene/Ch15q11-q13
		Fragile X	<i>FMR1/Ch X</i>
		Rett syndrome	<i>MECP2/Ch X</i>
Biochemical errors	Myopathies	Mitochondrial myopathies: Leber hereditary optic neuropathy; X-linked kinky-hair disease; Leigh syndrome; Kerns-Sayre syndrome; myoneurogastrointestinal disorder with encephalopathy	Mitochondrial DNA point mutations
		Nemaline myopathy	<i>TPM3, NEB</i>
		Central core disease	Ryanodine receptor gene
		Dopamine $\beta$ -hydroxylase deficiency	<i>DBH</i>
		Menkes	<i>MNK</i>
	Neurotransmitter deficiencies	Fabry disease	<i>GLA</i>
		Diabetes	
	Storage disorders	Addison disease/Cushing disease	
		Thyroid disorders	
	Unknown	Genetic or autoimmune or postinfectious ?	Autism
CVS			
Functional abdominal pain			
CFS			
POTS			
Sudden infant death syndrome			
Late-onset alveolar hypoventilation with obesity and hypothalamic dysfunction			
Prematurity			

Although there is no immunologic problem, ectodermal structures, skin and bone, heal poorly. Fractures are slow to heal, and large weight-bearing joints seem particularly susceptible to repeated trauma and infection. Temperature sensation is also decreased or absent, but deep-tendon reflexes are usually intact. Hypotonia and delayed developmental milestones are frequent in the early years, and there can be severe learning problems, often associated with hyperactivity. For patients with CIPA/HSAN type IV, the prognosis for independent function depends on the ability to manage secondary clinical problems, especially the orthopedic issues.

#### Allgrove Syndrome

Allgrove syndrome is a rare autosomal recessive syndrome that was first described in 1978.<sup>39</sup> Initially, it was also termed the “triple-A syndrome” because it was characterized by the triad of adrenocorticotrophic hormone-resistant adrenal insufficiency, achalasia, and alacrima. However, because it is now appreciated that autonomic dysfunction is also a feature, the term “4-A syndrome” has been considered more appropriate.<sup>40,41</sup> All components are not present in every patient, and age at onset is variable. The syndrome can present in the first decade of life with severe hypoglycemic episodes, which

can cause seizures or death, or dysphagia secondary to achalasia and decreased oral secretions. However, recognition of both achalasia and adrenocorticotrophic hormone insensitivity may not be appreciated until adolescence or even adulthood.<sup>42,43</sup> Many patients have progressive neurologic findings that consist of sensorimotor degeneration, optic neuropathy, and cerebellar features, as well as predominant abnormalities in the parasympathetic ANS.<sup>40,41</sup> The autonomic ocular findings include alacrima, keratoconjunctivitis sicca, lacrimal gland atrophy, pupillary abnormalities with hypersensitivity to dilute pilocarpine, and inappropriate accommodation.<sup>43–45</sup> Autonomic dysfunction also results in orthostatic hypotension with preservation of compensatory tachycardia and affects secretions so that sweating and oral secretions are diminished and males suffer sexual impotence.<sup>46</sup>

The Allgrove locus is on chromosome 12q13.<sup>45–47</sup> Mutations have been found in the *AAAS* gene, which codes for the WD-repeat-containing ALADIN (alacrima-achalasia-adrenal insufficiency-neurologic disorder) protein.<sup>48</sup> It is interesting to note that there is significant clinical variability between patients with the same *AAAS* mutation, suggesting genetic heterogeneity.

### *Disorders With Cardiorespiratory Dysregulation*

Disorders with cardiorespiratory dysregulation as their prominent feature affect breathing control. Thus, their consequences can be fatal. One of these disorders, congenital central hypoventilation syndrome (CCHS), is described below.

CCHS was first described in 1970 and soon thereafter referred to by the literary misnomer "Ondine's curse."<sup>49,50</sup> It typically presents in the newborn period with cyanosis during sleep, although those who are more severely affected hypoventilate awake and asleep with resultant hypercarbia and hypoxemia.<sup>50</sup> With compromised ventilatory and arousal responses to hypercarbia and hypoxemia, patients do not increase their minute ventilation nor perceive the physiologic compromise from breath-holding or exercise.

The mainstay of management to optimize neurodevelopmental outcome is tracheostomy with mechanical ventilation.<sup>50</sup> Diaphragm pacing is a daytime alternative for the child who requires ventilation 24 hours/day or potentially a nighttime alternative for the older adolescent or young adult who requires ventilation 12 hours/day. Mask ventilation and negative-pressure ventilation are other options for the child who requires ventilation only during sleep, although the transition to mask ventilation is better delayed until the child is old enough to understand the need to wear the mask for life support.<sup>50</sup>

In addition to its prominent effect on cardiorespiratory regulation, children with CCHS often have symptoms of diffuse ANS dysfunction that affect heart rate and blood pressure responses, gastrointestinal motility, and other homeostatic functions including sweating and body-temperature regulation.<sup>51–53</sup> Altered perceptions of pain and anxiety and ophthalmologic abnormalities including strabismus, altered pupillary responses, and accommodation have been described also.<sup>51,54–56</sup> Although children with CCHS can experience an overall good quality of life, neurodevelopmental outcome can vary as a result of ANS dysregulation specific to CCHS or chronic/intermittent hypoxemia.<sup>50</sup>

CCHS is considered a unique genetic entity with diffuse autonomic dysregulation, Hirschsprung disease in ~20% of cases, various tumors of neural crest origin in ~5% of cases, and characteristic facies.<sup>54,57–59</sup> Individuals with the CCHS phenotype are heterozygous for a *PHOX2B* gene mutation located on chromosome 4p12.<sup>60–64</sup> In 90% to 95% of CCHS cases there is a polyalanine expansion mutation in exon 3, and in 5% to 10% of cases there is a unique mutation. A relationship between polyalanine-repeat length and the severity of autonomic dysfunction, as indicated by the number of associated autonomic symptoms, has been noted.<sup>62,64</sup> Subjects with unique mutations in *PHOX2B* have a higher rate of Hirschsprung disease, higher frequency of ventilation requirement for 24 hours/day, and more fre-

quent neural crest tumors than in the polyalanine expansion-mutation group.<sup>61,62,64–66</sup>

A polymerase chain reaction–based DNA test is clinically available for diagnosis of CCHS. This test can be used to identify probands and the presence of mosaicism in parents and for prenatal diagnosis. The assay also has applicability in diagnosing CCHS in adults with unexplained hypercarbia or control of breathing deficits.<sup>67</sup>

### *Chromosomal Disorders*

Chromosomal disorders usually have multisystem perturbations, and it is increasingly appreciated that autonomic dysfunction can be a feature of many of these disorders because of either expansions or deletions of particular genes. One illustrative disorder is Rett syndrome.

Rett syndrome is a neurodevelopmental disorder that predominantly affects females. Mutations in the gene encoding methyl-CpG-binding protein 2 (*MECP2*) on the X chromosome have been identified in 95% of girls with the Rett syndrome phenotype.<sup>68,69</sup> The diagnosis is based on clinical criteria.<sup>70</sup> The phenotype typically includes normal development until 6 to 18 months of age, and then there is regression with slowing of head circumference growth, loss of language, development of stereotypical hand movements, and gait and truncal apraxia. Some girls also develop electroencephalogram abnormalities, seizures, spasticity, and scoliosis.

The autonomic features include cardiorespiratory dysregulation and abnormal blood pressure responses. Respiratory dysregulation includes hyperventilation, apnea, breath-holding, and rapid shallow-breathing.<sup>71–82</sup> During wakefulness, breathing dysrhythmias are associated with agitation or excitement as well as other motor functions. During sleep, polysomnography has documented increased frequency of desaturation events and periodic breathing. Girls with Rett syndrome who demonstrate hypoxemia without hypercarbia, awake or asleep, should be treated with supplemental oxygen. Likewise, girls who demonstrate evidence for obstructive sleep apnea (without a treatable cause) should be treated with mask bilevel positive airway pressure during sleep. In so doing, the girls will be protected from the sequelae of acute and chronic intermittent hypoxemia and hypercarbia.

An imbalance of sympathovagal input has been reported.<sup>77,81</sup> Decreased cardiac vagal tone and cardiac sensitivity to baroreflex have been identified and result in unopposed sympathetic activity with extreme hypertension and tachycardia. Additional support for autonomic dysregulation comes from observations of decreased heart rate variability, prolongation of corrected QT intervals, and sinus bradycardia.<sup>83–86</sup>

Despite survival into adulthood, 26% of all deaths from Rett syndrome are sudden and unexpected, and cardiac causes for sudden death have been suggested

because of autonomic dysregulation.<sup>82,86,87</sup> Additional assessment of heart rate variability and control of breathing is needed to elucidate the mechanisms involved in sudden death.

### **Autonomic Disorders Associated With Biochemical Errors**

Mitochondrial encephalomyopathies are heterogeneous multisystem disorders characterized by structural or biochemical defects in the mitochondria that impair normal oxidative phosphorylation.<sup>88</sup> Common symptoms include hypotonia, ophthalmoplegia, seizures, pyramidal and extrapyramidal signs, psychomotor regression, ataxia, stroke-like episodes, lactic acidosis, and sometimes endocrinopathies.<sup>88,89</sup> In general, involvement of the ANS has not been stressed; however, on occasion, the autonomic abnormalities can be so severe that they can overshadow the myopathic features and may delay definitive diagnosis.<sup>89</sup> Autonomic features including vomiting, impaired respiratory control, and cardiac arrhythmia have been observed with Leigh syndrome and Kerns-Sayre syndrome and in myoneurogastrointestinal disorder with encephalopathy.<sup>90–92</sup> In addition, autonomic or visceral features such as cardiac conduction defects or hypothermia and feeding problems may occasionally occur in other mitochondrial diseases including Leber hereditary optic neuropathy<sup>93</sup> and X-linked recessive kinky-hair disease.<sup>94</sup> In addition, decreased lacrimation, vasomotor disturbances characterized by blotchy erythema and skin mottling, altered sweating, and postural hypotension have also been noted in individuals in whom muscle biopsy has verified abnormal respiratory-chain enzymes.<sup>89</sup>

Because mitochondrial disorders are multisystem diseases, dysfunction of the ANS may be a result of structural abnormalities of mitochondria within the central or peripheral nervous system.<sup>95</sup> Diagnosis is verified by biochemical assays for mitochondrial enzyme activities.

### **Unknown**

#### *Autism*

Autism is a complex neurodevelopmental disorder that produces social, behavioral, and language impairment. Approximately three quarters of the children with autism have mental retardation, and one third have seizures. It affects more males than females.<sup>96</sup> However, in addition to traditional neurodevelopmental symptoms, it is now appreciated that autism also produces symptoms attributable to other organ systems. Some of these manifestations, including unexplained constipation or diarrhea, urinary retention, cold and clammy extremities, and sleep disturbances, suggest underlying autonomic dysfunction.<sup>97</sup> These children seem to have impaired parasympathetic activity resulting in unrestrained sympathetic activity.<sup>97</sup> Autonomic tests have demonstrated blunted autonomic arousal responses to visual and au-

ditory social stimuli.<sup>98,99</sup> In addition, there is low baseline cardiac vagal tone and low cardiac baroreceptor sensitivity, resulting in hyperactive heart rate and blood pressure responses.<sup>97</sup> However, paradoxically, children with autistic behavior are less flexible in their autonomic adaptation to attention-demanding tasks and demonstrate less decrease in heart rate variability than normal controls during periods of task performance.<sup>97</sup>

In support of central autonomic dysfunction, pathologic examinations have revealed abnormalities in central structures often associated with autonomic control, such as the brainstem, the amygdala, the limbic system, the cerebellum, and the prefrontal lobes.<sup>100</sup> In addition, abnormal levels of monoaminergic and cholinergic neurotransmitters, including norepinephrine, dopamine, acetylcholine, serotonin, and various neuropeptides, have been reported.<sup>97</sup> In addition, secretin and oxytocin, both polypeptide neurotransmitters that cross the blood-brain barrier, have each been reported to improve some of the symptoms in different autistic subgroups.<sup>101,102</sup> The reversal of symptoms through agents that seem to alter central autonomic function further supports direct involvement of autonomic centers in autism.

#### *Functional Gastrointestinal Disorders*

By definition, in functional gastrointestinal disorders, there are no anatomic, inflammatory, or biochemical abnormalities to explain the symptoms.<sup>103</sup> Although their pathophysiology is generally unknown, it is hypothesized that the interaction between specific psychosocial factors and gut innervation through the brain-gut axis, including both neuroendocrine and ANS, may produce an abnormality of gut function. The gut dysfunction may be expressed by abnormal motility, visceral hyperalgesia, or both.

The functional gastrointestinal disorders of childhood are classified according to the ROME II criteria in 4 groups and several subgroups.<sup>104</sup> The groups include (1) vomiting, (2) abdominal pain, (3) functional diarrhea, and (4) disorders of defecation. Although all of these may be associated with autonomic dysfunction, the evidence is clearest for cyclic vomiting syndrome (CVS) and functional abdominal pain.

#### *CVS*

CVS is characterized by severe, discrete episodes of nausea, vomiting, and lethargy of unclear etiology, with baseline return to health between episodes.<sup>105–107</sup> It is predominantly a disease of childhood, affecting ~1.9% of school-aged children and frequently evolves into migraine headaches in adulthood.<sup>105</sup> Episodes often are triggered by emotional or physical stress, during which many autonomic symptoms are exhibited, including increased salivation, pallor, increased sweating, nausea, increased blood pressure, diarrhea, and dizziness.<sup>107,108</sup> A

prodrome of headaches, photophobia, or vertigo often precedes the period of vomiting.<sup>105-108</sup> Autonomic testing has demonstrated abnormalities characterized by increased sympathetic modulation as reflected in heart rate variability and postural intolerance.<sup>109,110</sup> Although some consider CVS to be a migraine variant, these studies suggest an autonomic basis.<sup>110</sup> The cause of CVS is unknown, but genetic factors have been suggested, because a subset of children with CVS seems to have maternal inheritance and an associated mitochondrial DNA variation.<sup>111</sup>

#### *Functional Abdominal Pain*

The association of functional abdominal pain and autonomic dysfunction in children is still poorly understood. It is not uncommon for children with functional gastrointestinal disorders to report various autonomic symptoms including dizziness, headaches, flushing, sweating, Raynaud's phenomena, and severe fatigue.<sup>112</sup> In addition, in a subset of children with functional abdominal pain, postural orthostatic tachycardia syndrome (POTS) and mild peripheral neuropathy have been noted.<sup>113</sup> An operational definition of POTS includes symptoms of orthostatic intolerance, such as fatigue, light-headedness, nausea, vomiting, headache, palpitations, and tremulousness, associated with increased heart rate exceeding 30 beats per minute or to a heart rate >120 beats per minute within 10 minutes of head-up tilt.<sup>114</sup> Thus, patients with POTS also report a variety of gastrointestinal symptoms such as nausea, bloating, early satiety, abdominal pain, and other gastrointestinal manifestations.<sup>115</sup> Furthermore, patients with functional abdominal pain often respond favorably to treatments directed toward ANS dysfunction such as relaxation and guided imagery and medical treatment such as increasing dietary salt, fludrocortisone, and  $\beta$  blockers.<sup>115</sup>

#### *CFS*

CFS is now recognized as a distinct disorder with specific diagnostic criteria.<sup>116</sup> It is characterized by chronic or relapsing fatigue, lasting for at least 6 months, causing impaired overall physical and mental functioning. Often there is a paucity of physical findings resulting in CFS being a diagnosis of exclusion. Self-reported symptoms can include cognitive difficulties, muscle pain, joint pain, headache, sleep disturbance, poor sleep, and postexercise malaise, as well as a variety of gastrointestinal symptoms.<sup>116-118</sup>

Onset of symptoms often follows an infectious disease and may be related to inflammatory mediators.<sup>119,120</sup> According to a report generated from a Centers for Disease Control and Prevention workshop,<sup>116</sup> pediatric CFS patients are mostly teenage females who report a preceding inflammatory condition. Similar to the adult experience, orthostatic intolerance in adolescents with CFS

is consistent with POTS.<sup>118,121</sup> CFS may represent a severe form of POTS in adolescents, and the autonomic findings may be related to circulatory abnormalities at rest and during orthostasis. Stewart et al<sup>121</sup> have demonstrated loss of heart rate variability consistent with vagal withdrawal, increased blood pressure variability consistent with enhanced modulation of sympathetic tone, and impaired baroreflex.

Because no cause for CFS has been identified and the pathophysiology remains unknown, treatment programs are directed at relief of symptoms, with the goal of the patient regaining some level of preexisting function and well-being. Nonpharmacologic therapies include light exercise and patient education. Pharmacologic therapy is directed toward the relief of specific symptoms experienced by the individual patient. Fludrocortisone has been prescribed for patients with CFS who have had a positive tilt-table test, but it may need to be combined with other treatments such as midodrine, an agent that directly increases blood pressure, as well as increased salt and water intake.

#### **EVALUATION AND THERAPEUTIC INTERVENTIONS**

It is beyond the scope of this article to give extensive descriptions of the various diagnostic techniques that can be used to differentiate and characterize the various autonomic disorders. In addition, there is still a need to reach consensus among investigators as to which techniques provide the most accurate means of assessment in the pediatric population. To this end, the American Autonomic Society created a task force for the specific purpose of providing a consensus statement regarding assessment guidelines.

In the interim, it is recommended that evaluation of the child suspected of having autonomic dysfunction start with a comprehensive history and be accompanied by a clinical examination that focuses on neurologic features. Questions and examination should attempt to discern if the problem is static or progressive, if there are peripheral and/or central autonomic disturbances, if there are associated sensory problems, and if there is muscle weakness. Because decreased response to pain can be caused by emotional indifference, as well as true insensitivity resulting from neuronal dysfunction, the response to particular injuries should be documented. Although the indifferent patient might not respond to a fall or laceration, the response to a fracture or a burn is expected to be appropriate, because deep pain fibers are intact. Objective tests also can be performed to verify neurologic dysfunction, such as the histamine test and the sympathetic skin response. The intradermal histamine test still remains a good screening test for sensory dysfunction caused by small-fiber neuropathy, and an abnormal response (ie, absence of the axon flare) can be seen in all the HSN types.

To further assess autonomic dysfunction and identify

sympathetic or parasympathetic deficits, a few relatively simple “bedside” tests can be performed. Active standing or a passive head-up tilt evaluates orthostatic cardiovascular control. For a detailed description of other autonomic tests that are used in the adult population, such as metronomic breathing (which challenges parasympathetic cardiovascular modulation) and the Valsalva maneuver (which tests baroreflex buffer capacity and reflex bradycardia), the reader is referred to standard textbooks.<sup>2-4</sup> However, many of these tests cannot be administered to the pediatric patient, for whom we desire noninvasive quantitative tests that require minimal participation and cooperation.

Although gene identification holds the promise of eventually yielding more specific treatments for some of the autonomic disorders, at present most treatments are supportive. If the autonomic perturbations seem to involve only one organ system, then it is reasonable that evaluation and therapy decisions will be system specific. In some instances, the treatments that have been found effective in the genetic autonomic disorders such as the HSANs (in particular, FD) have been tried in the other autonomic disorders. For episodic signs of central sympathetic storm that include symptoms such as tachycardia, hypertension, diaphoresis, and hyperpyrexia, central  $\alpha$  agonists such as clonidine have been tried. However, when there is multisystem involvement, then a more comprehensive assessment with careful evaluation of the autonomic and sensory systems is warranted, because choices for therapeutic interventions can be complicated and treatment for one system may provoke perturbations in another. In such cases, a comprehensive approach is needed for optimal management.

## CONCLUSIONS

The ANS innervates every organ in the body, and thus its effects are pervasive and perturbations can cause a broad spectrum of symptoms. The list of pediatric disorders with autonomic dysfunction, primary or secondary, is continuing to expand. Therefore, to increase our diagnostic acumen in this area and develop better treatments, it is essential that we better understand the ANS, its normal functioning, and the role of its various components.

The goal of this review is to promote awareness of ANS disorders that affect the pediatric population. We are not describing new disorders; rather, we are providing a new perspective on a number of well-recognized pediatric disorders, which may lead to innovative treatment approaches such as correcting neurotransmitter imbalances. We are continuing to learn about the various signs and symptoms of autonomic dysfunction in the young child, and there still remains a need for ongoing research into the genetics and pathophysiology of the various disorders and consensus regarding techniques

for objective assessment of autonomic and sensory function in the pediatric population.

## REFERENCES

- Langley JN. *The Autonomic Nervous System: Part I*. Cambridge, United Kingdom: Heffer; 1921
- Low PA, ed. *Clinical Autonomic Disorders: Evaluation and Management*. 2nd ed. Philadelphia, PA: Lippincott Raven; 1997
- Robertson D, Biaffioni I, Burnstock G, Low PA, eds. *Primer of the Autonomic Nervous System*. San Diego, CA: Elsevier Academic Press; 2004
- Appenzeller O. *The Autonomic Nervous System*. Amsterdam, Netherlands: Elsevier Science; 1990
- Dancis J. Familial dysautonomia (Riley-Day syndrome). In: Bannister R, ed. *Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System*. Oxford, United Kingdom: Oxford University Press; 1983:615–639
- Axelrod FB. Genetic disorders as models to understand autonomic dysfunction. *Clin Auton Res*. 2002;12(suppl 1):1
- Axelrod FB. Hereditary sensory and autonomic neuropathies: familial dysautonomia and other HSANs. *Clin Auton Res*. 2002; 12(suppl 1):2–14
- Riley CM, Day RL, McL Greeley D, Langford WS. Central autonomic dysfunction with defective lacrimation: report of 5 cases. *Pediatrics*. 1949;3:468–477
- Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. *Arch Neurol*. 1960;2:511–527
- Pick J. *The Autonomic Nervous System*. Philadelphia, PA: Lippincott; 1970
- Loewy AS. Central autonomic pathways. In: Loewy AS, Spyer KM, eds. *Central Regulation of Autonomic Functions*. New York, NY: Oxford University Press; 1990:88–103
- Eldlund T, Jessell TM. Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. *Cell*. 1999;96:211–224
- Goridis C, Brunet JF. Transcriptional control of neurotransmitter phenotype. *Curr Opin Neurobiol*. 1999;9:47–53
- Sommer L, Shah N, Rao M, Anderson D. The cellular function of MASH1 in autonomic neurogenesis. *Neuron*. 1995;15: 1245–1258
- Tiveron M, Hirsch M, Brunet J. The expression pattern of the transcription factor Phox2 delineates synaptic pathways of the autonomic nervous system. *J Neurosci*. 1996;16:7649–7690
- Levi-Montalcini R. The morphological effects of immunosympathectomy. In: Steiner G, Schonbam E, eds. *Immunosympathectomy*. Amsterdam, Netherlands: Elsevier; 1972:55–78
- Thoenen H, Barde YA. Physiology of nerve growth factor. *Physiol Rev*. 1980;60:1284–1335
- Hilz MJ, Devinsky O, Doyle W, Mauerer A, Dutsch M. Decrease of sympathetic cardiovascular modulation after temporal lobe epilepsy surgery. *Brain*. 2002;25:985–995
- Benarroch EE, Chang FL. Central autonomic disorders. *J Clin Neurophysiol*. 1993;10:39–50
- Dyck P, Ohta M. Neuronal atrophy and degeneration predominantly affecting peripheral sensory neurons. In: Dyck PJ, Thomas PK, Lambert EH, eds. *Peripheral Neuropathy*. Vol II. Philadelphia, PA: WB Saunders; 1975:791
- Anderson SL, Coli R, Daly IW, et al. Familial dysautonomia is caused by mutations of the IKAP gene. *Am J Hum Genet*. 2001;68:753–758
- Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the *IKBKAP* gene causes familial dysautonomia. *Am J Hum Genet*. 2001;68:598–605
- Cuajungco MP, Leyne M, Mull J, et al. Cloning, characterization, and genomic structure of the mouse *IKBKAP* gene. *DNA Cell Biol*. 2001;20:579–586

24. Leyne M, Mull J, Gill SP, et al. Identification of the first non-Jewish mutation in familial dysautonomia. *Am J Med Genet A*. 2003;118:305–308
25. Hilz MJ, Axelrod FB. Quantitative sensory testing of thermal and vibratory perception in familial dysautonomia. *Clin Auton Res*. 2000;10:177–183
26. Axelrod FB, Iyer K, Fish I, Pearson J, Sein ME, Spielholz N. Progressive sensory loss in familial dysautonomia. *Pediatrics*. 1981;65:517–522
27. Axelrod FB. Autonomic and sensory disorders. In: Emory AEH, Rimoin DL, eds. *Principles and Practice of Medical Genetics*. 3rd ed. Edinburgh, Scotland: Churchill Livingstone; 1996: 397–411
28. Smith AA, Hirsch JJ, Dancis J. Responses to infused methacholine in familial dysautonomia. *Pediatrics*. 1965;36:225–230
29. Bickel A, Axelrod FB, Schmetz M, Marthal H, Hilz MJ. Dermal microdialysis provides evidence for hypersensitivity to noradrenaline in patients with familial dysautonomia. *J Neurol Neurosurg Psychiatry*. 2002;73:299–302
30. Filler J, Smith AA, Stone S, Dancis J. Respiratory control in familial dysautonomia. *J Pediatr*. 1965;81:509–516
31. Edelman NH, Cherniack NS, Lahiri S, et al. The effects of abnormal sympathetic nervous function upon the ventilatory response to hypoxia. *J Clin Invest*. 1970;41:1153–1165
32. Maayan C, Carley DW, Axelrod FB, Grimes J, Shannon DC. Respiratory system stability and abnormal carbon dioxide homeostasis. *J Appl Physiol*. 1992;72:1186–1193
33. Bernardi L, Hilz M, Stemper B, Passino C, Welsch G, Axelrod FB. Respiratory and cerebrovascular responses to hypoxia and hypercapnia in familial dysautonomia. *Am J Respir Crit Care Med*. 2002;167:141–149
34. Welton W, Clayson D, Axelrod FB, Levine DB. Intellectual development and familial dysautonomia. *Pediatrics*. 1979;63: 708–712
35. Axelrod FB, Goldberg JD, Ye XY, Maayan C. Survival in familial dysautonomia: impact of early intervention. *J Pediatr*. 2002;141:518–523
36. Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the NTRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. *Nat Genet*. 1996;13:485–488
37. Oddoux C, Wang J, Clayton CM, et al. Genetic heterogeneity in hereditary and autonomic sensory neuropathy (HSAN4) [abstract]. *Society of Human Genetics*. October 1999
38. Pinsky L, DiGeorge AM. Congenital familial sensory neuropathy with anhidrosis. *J Pediatr*. 1966;68:1–13
39. Allgrove J, Clayden GS, Grant DB, Macaulay JC. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. *Lancet*. 1978;1(8077):1284–1286
40. Chu ML, Berlin D, Axelrod FB. Allgrove syndrome: documenting cholinergic dysfunction by autonomic tests. *J Pediatr*. 1996;129:156–159
41. Kimber J, McLean BN, Prevett M, Hammans SR. Allgrove or 4 “A” syndrome: an autosomal recessive syndrome causing multisystem neurological disease. *J Neurol Neurosurg Psychiatry*. 2003;74:654–657
42. Moore PS, Couch RM, Perry YS, Shuckett EP, Winter JS. Allgrove syndrome: an autosomal recessive syndrome of ACTH insensitivity, achalasia and alacrima. *Clin Endocrinol (Oxf)*. 1991;34:107–114
43. Mullaney PB, Weatherhead R, Millar L, et al. Keratoconjunctivitis sicca associated with achalasia of the cardia, adrenocortical insufficiency, and lacrimal gland degeneration: keratoconjunctivitis sicca secondary to lacrimal gland degeneration may parallel degenerative changes in esophageal and adrenocortical function. *Ophthalmology*. 1998;105:643–650
44. Tsilou E, Stratakis CA, Rubin BI, Hay BN, Patronas N, Kaiser-Kupfer MI. Ophthalmic manifestations of Allgrove syndrome: report of a case. *Clin Dysmorphol*. 2001;10:231–233
45. Brooks BP, Kleta R, Caruso RC, Stuart C, Ludlow J, Stratakis CA. Triple-A syndrome with prominent ophthalmic features and a novel mutation in the AAAS gene: a case report. *BMC Ophthalmol*. 2004;4:7
46. Houlden H, Smith S, De Carvalho M, et al. Clinical and genetic characterization of families with triple A (Allgrove) syndrome. *Brain*. 2002;125:2681–2690
47. Weber A, Wienker TF, Jung M, et al. Linkage of the gene for the triple A syndrome to chromosome 12q13 near the type II keratin gene cluster. *Hum Mol Genet*. 1996;5:2061–2066
48. Sandrini F, Farmakidis C, Kirschner LS, et al. Spectrum of mutations of the AAAS gene in Allgrove syndrome: lack of mutations in six kindreds with isolated resistance to corticotropin. *J Clin Endocrinol Metab*. 2001;86:5433–5437
49. Mellins RB, Balfour HH Jr, Turino GM, Winters RW. Failure of automatic control of ventilation (Ondine’s curse): report of an infant born with this syndrome and review of the literature. *Medicine (Baltimore)*. 1970;49:487–504
50. Weese-Mayer DE, Shannon DC, Keens TG, Silvestri JM. American Thoracic Society statement on the diagnosis and management of idiopathic congenital central hypoventilation syndrome. *Am J Respir Crit Care Med*. 1999;160:368–373
51. Weese-Mayer DE, Silvestri JM, Huffman AD, et al. Case/control family study of autonomic nervous system dysfunction in idiopathic congenital central hypoventilation syndrome. *Am J Med Genet*. 2001;100:237–245
52. Trang H, Girard A, Laude D, Elghozi JL. Short-term blood pressure and heart rate variability in congenital central hypoventilation syndrome. *Clin Sci (Lond)*. 2005;108:225–230
53. Faure C, Viarme F, Cargill G, et al. Abnormal esophageal motility in children with congenital central hypoventilation syndrome. *Gastroenterology*. 2002;122:1258–1263
54. Weese-Mayer DE, Silvestri JM, Menzies LJ, Morrow-Kenny AS, Hunt CE, Hauptman SA. Congenital central hypoventilation syndrome: diagnosis, management, and long-term outcome in thirty-two children. *J Pediatr*. 1992;120:381–387
55. Goldberg DS, Ludwig IH. Congenital central hypoventilation syndrome: ocular findings in 37 children. *J Pediatr Ophthalmol Strabismus*. 1996;33:175–180
56. Pine DS, Weese-Mayer DE, Silvestri JM, Davies M, Whitaker AH, Klein DF. Anxiety and congenital central hypoventilation syndrome. *Am J Psychiatry*. 1994;151:864–870
57. Haddad GG, Mazza NM, Defendini R, et al. Congenital failure of automatic control of ventilation, gastrointestinal motility and heart rate. *Medicine (Baltimore)*. 1978;57:517–526
58. Bower RJ, Adkins JC. Ondine’s curse and neurocristopathy. *Clin Pediatr (Phila)*. 1980;19:665–668
59. Todd ES, Weinberg SM, Berry-Kravis EM, et al. Facial phenotype in children and young adults with PHOX2B determined congenital central hypoventilation syndrome: quantitative pattern of dysmorphology. *Pediatr Res*. 2006;59:39–45
60. Weese-Mayer DE, Berry-Kravis EM, Marazita ML. In pursuit (and discovery) of a genetic basis for congenital central hypoventilation syndrome. *Respir Physiol Neurobiol*. 2005;149: 73–82
61. Amiel J, Laudier B, Attie-Bitach T, et al. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene *PHOX2B* in congenital central hypoventilation syndrome. *Nat Genet*. 2003;33:459–461
62. Weese-Mayer DE, Berry-Kravis EM, Zhou L, et al. Idiopathic congenital central hypoventilation syndrome: analysis of genes pertinent to early autonomic nervous system embryologic development and identification of mutations in *PHOX2B*. *Am J Med Genet A*. 2003;123:267–278
63. Sasaki A, Kanai M, Kijima K, et al. Molecular analysis of

- congenital central hypoventilation syndrome. *Hum Genet.* 2003;114:22–26
64. Matera I, Bachtetti T, Puppo F, et al. *PHOX2B* mutations and polyalanine expansions correlate with the severity of the respiratory phenotype and associated symptoms in both congenital and late onset central hypoventilation syndrome. *J Med Genet.* 2004;41:373–380
  65. Trochet D, O'Brien LM, Gozal D, et al. *PHOX2B* genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. *Am J Hum Genet.* 2005;76:421–426
  66. Berry-Kravis EM, Zhou L, Rand CM, Weese-Mayer DE. Unique *PHOX2B* mutations in children with congenital central hypoventilation syndrome (CCHS) [abstract]. *Pediatr Res.* 2005;57:2289
  67. Weese-Mayer DE, Berry-Kravis EM, Zhou L. Adult identified with CCHS-mutation in *PHOX2B* gene and late onset CHS. *Am J Respir Crit Care Med.* 2005;171:88
  68. Fang P, Jin W, Glaze DG, Percy A, Zoghbi HY, Roa BB. *MECP2* gene deletions account for ~10% of Rett syndrome cases [abstract]. *Am Soc Hum Genet.* 2004;476:2652
  69. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked *MECP2*, encoding methyl-CpG-binding protein 2. *Nat Genet.* 1999;23:185–188
  70. Kerr AM, Nomura Y, Armstrong D, et al. Guidelines for reporting clinical features in cases with *MECP2* mutations. *Brain Dev.* 2001;23:208–211
  71. Cirignotta F, Lugaresi E, Montagna P. Breathing impairment in Rett syndrome. *Am J Med Genet.* 1986;24(suppl 1):167–173
  72. Southall DP, Kerr AM, Tirosch E, Amos P, Lang MH, Stephenson JBP. Hyperventilation in the awake state: potentially treatable component of Rett syndrome. *Arch Dis Child.* 1988;63:1039–1048
  73. Kerr AM. A review of the respiratory disorder in the Rett syndrome. *Brain Dev.* 1992;14(suppl):S43–S45
  74. Elian M, Rudolf NM. EEG and respiration in Rett syndrome. *Acta Neurol Scand.* 1991;83:123–128
  75. Julu POO, Kerr AM, Hansen S, Apartopoulos F, Jamal GA. Functional evidence of brain stem immaturity in Rett syndrome. *Eur Child Adolesc Psychiatry.* 1997;6(suppl 1):47–54
  76. Kerr AM, Julu POO. Recent insights into hyperventilation from the study of Rett syndrome. *Arch Dis Child.* 1999;80:384–387
  77. Julu POO, Kerr AM, Apartopoulos F, et al. Characterization of breathing and associated central autonomic dysfunction in the Rett disorder. *Arch Dis Child.* 2001;85:29–37
  78. Glaze DG, Frost JD Jr, Zoghbi HY, Percy AK. Rett's syndrome: characterization of respiratory patterns and sleep. *Ann Neurol.* 1987;21:377–382
  79. Schlüter B, Aguigah G, Buschatz D, Trowitzsch E, Aksu F. Polysomnographic recordings of respiratory disturbances in Rett syndrome. *J Sleep Res.* 1995;4(suppl 1):203–207
  80. Marcus CL, Carroll JL, McColley SA, et al. Polysomnographic characteristics of patients with Rett syndrome. *J Pediatr.* 1994;125:218–224
  81. Nomura Y, Kimura K, Arai H, Segawa M. Involvement of the autonomic nervous system in the pathophysiology of Rett syndrome. *Eur Child Adolesc Psychiatry.* 1997;6(suppl 1):42–45
  82. Weese-Mayer DE, Boothby CM, Lieske SP, et al. Autonomic nervous system dysregulation in breathing and heart rate in girls with Rett syndrome [abstract]. *Pediatr Res.* 2005;57:1210
  83. Guideri F, Acampa M, DiPerri T, Zappella M, Hayek Y. Progressive cardiac dysautonomia observed in patients affected by classic Rett syndrome and not in the preserved speech variant. *J Child Neurol.* 2001;16:370–373
  84. Sekul EA, Moak JP, Schultz RJ, Glaze DG, Dunn JK, Percy AK. Electrocardiographic findings in Rett syndrome: an explanation for sudden death? *J Pediatr.* 1994;125:80–82
  85. Ellaway CJ, Sholler G, Leonard H, Christodoulou J. Prolonged QT interval in Rett syndrome. *Arch Dis Child.* 1999;80:470–472
  86. Guideri F, Acampa M, Hayek G, Zappella M, DiPerri T. Reduced heart rate variability in patients affected with Rett syndrome: a possible explanation for sudden death. *Neuropediatrics.* 1999;30:146–148
  87. Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. *Eur Child Adolesc Psychiatry.* 1997;6(suppl 1):71–74
  88. DiMauro S. Mitochondrial myopathies. In: Rosenberg RN, Pruisner SB, DiMauro S, Barachi RL, Kunkel LM, eds. *The Molecular and Genetic Basis of Neurological Diseases.* Boston, MA: Butterworth-Heinemann; 1993:665–694
  89. Zelnik N, Axelrod FB, Leshinsky E, Griebel ML, Kolodny E. Mitochondrial encephalopathies presenting with features of autonomic and visceral dysfunction. *Pediatr Neurol.* 1996;14:251–254
  90. Berenberg RA, Pellock JM, DiMauro S, et al. Lumping or splitting? "Ophthalmoplegia plus" or Kearns-Sayre syndrome? *Ann Neurol.* 1977;1:37–43
  91. Pincus JH. Subacute necrotizing encephalomyopathy (Leigh's disease): a consideration of clinical features and etiology. *Dev Med Neurol.* 1972;14:87–101
  92. Bardosi A, Creutzfeldt W, DiMauro S, et al. Myo-neurogastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome c-oxidase: a new mitochondrial multisystem disorder. *Acta Neuropathol (Berl).* 1987;74:248–258
  93. Newman NJ, Wallace DC. Mitochondria and Leber's hereditary optic neuropathy. *Am J Ophthalmol.* 1990;109:726–730
  94. Kodama H. Recent developments in Menkes disease. *J Inherit Metab Dis.* 1993;16:791–799
  95. Schroeder MJ. Neuropathy associated with mitochondrial disorders. *Brain Pathol.* 1993;3:177–190
  96. Nelson KB, Grether JK, Croen LA, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. *Ann Neurol.* 2001;49:597–606
  97. Ming X, Julu P, Brimacombe M, Connor S, Daniels M. Reduced cardiac parasympathetic activity in children with autism. *Brain Dev.* 2005;27:509–516
  98. Palkovitz RJ, Wiesenfeld AR. Differential autonomic responses of autistic and normal children. *J Autism Dev Disord.* 1980;10:347–360
  99. Hirstein W, Iversen P, Ramachandran VS. Autonomic responses of autistic children to people and objects. *Proc Biol Sci.* 2001;268:1883–1888
  100. Courchesne E. Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism [published correction appears in *Curr Opin Neurobiol.* 1997;7:568]. *Curr Opin Neurobiol.* 1997;7:269–278
  101. Lamson DW, Plaza SM. Transdermal secretin for autism: a case report. *Altern Med Rev.* 2001;6:311–313
  102. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. *Neuropsychopharmacology.* 2003;28:193–198
  103. Drossman DA. The functional gastrointestinal disorders and the Rome II process. *Gut.* 1999;45(suppl 2):II1–II15
  104. Li BU, Issenman RM, Sarna SK. Consensus statement: 2nd International Scientific Symposium on CVS. The Faculty of the 2nd International Scientific Symposium on Cyclic Vomiting Syndrome. *Dig Dis Sci.* 1999;44(8 suppl):9S–11S
  105. Stickler GB. Relationship between cyclic vomiting syndrome and migraine. *Clin Pediatr (Phila).* 2005;44:505–508

106. Stein MT, Katz RM, Jellinek MS, Olness K. Cyclic vomiting. *J Dev Behav Pediatr.* 2001;22:S139–S142
107. Haan J, Kors EE, Ferrari MD. Familial cyclic vomiting syndrome. *Cephalalgia.* 2002;22:552–554
108. Pfau BT, Li BU, Murray RD, Heitlinger LA, McClung HJ, Hayes JR. Differentiating cyclic from chronic vomiting patterns in children: quantitative criteria and diagnostic implications. *Pediatrics.* 1996;97:364–368
109. To J, Issenman RM, Kamath MV. Evaluation of neurocardiac signals in pediatric patients with cyclic vomiting syndrome through power spectral analysis of heart rate variability. *J Pediatr.* 1999;135:363–366
110. Rashed H, Abell TL, Familoni BO, Cardoso S. Autonomic function in cyclic vomiting syndrome and classic migraine. *Dig Dis Sci.* 1999;44(8 suppl):74S–78S
111. Wang Q, Ito M, Adams K, et al. Mitochondrial DNA control region sequence variation in migraine headache and cyclic vomiting syndrome. *Am J Med Genet A.* 2004;131:50–58
112. Chelimsky G, Chelimsky T. The role of autonomic testing in pediatric gastrointestinal disorders [abstract]. *J Pediatr Gastroenterol Nutr.* 2005;41:521
113. Chelimsky G, Boyle JT, Tusing L, Chelimsky TC. Autonomic abnormalities in children with functional abdominal pain: coincidence or etiology? *J Pediatr Gastroenterol Nutr.* 2001;33:47–53
114. Grubb BP, Kosinski DJ, Boehm K, Kip K. The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing. *Pacing Clin Electrophysiol.* 1997;20:2205–2212
115. Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA. Postural tachycardia syndrome: clinical features and follow-up study. *Mayo Clin Proc.* 1999;74:1106–1110
116. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med.* 1994;121:953–959
117. Carter BD, Edwards JF, Kronenberger WG, et al. Case control study of chronic fatigue in pediatric patients. *Pediatrics.* 1995;95:179–186
118. Rowe PC, Bou-Holaigah I, Kan JS, Calkins H. Is neurally mediated hypotension an unrecognized cause of chronic fatigue? *Lancet.* 1995;345:623–624
119. Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. *J Rheumatol.* 1997;24:372–376
120. Clements GB, McGarry F, Nairn C, Galbraith DN. Detection of enterovirus-specific RNA in serum: the relationship to chronic fatigue. *J Med Virol.* 1995;45:156–161
121. Stewart JM, Gewitz MH, Weldon A. Orthostatic intolerance in adolescent chronic fatigue syndrome. *Pediatrics.* 1999;103:116–121

---

## PRESCRIPTION-DRUG USE BY TEENS

“While teen smoking and drinking continue to drop, a new survey indicates that teenage abuse of prescription drugs has become ‘an entrenched behavior.’ For a third straight year, the Partnership for a Drug-Free America study showed that about one in five teens has tried prescription painkillers like Vicodin or OxyContin to get high—about 4.5 million teens. It also indicated that many teens feel experimenting with prescription drugs is safer than illegal highs. Forty percent said prescription medicines were ‘much safer’ than illegal drugs; 31% said there was ‘nothing wrong’ with using prescription drugs ‘once in a while.’”

**Associated Press. May 16, 2006**

Noted by JFL, MD

## Pediatric Autonomic Disorders

Felicia B. Axelrod, Gisela G. Chelimsky and Debra E. Weese-Mayer

*Pediatrics* 2006;118;309-321

DOI: 10.1542/peds.2005-3032

**This information is current as of October 16, 2006**

### Updated Information & Services

including high-resolution figures, can be found at:  
<http://www.pediatrics.org/cgi/content/full/118/1/309>

### References

This article cites 109 articles, 20 of which you can access for free at:  
<http://www.pediatrics.org/cgi/content/full/118/1/309#BIBL>

### Citations

This article has been cited by 1 HighWire-hosted articles:  
<http://www.pediatrics.org/cgi/content/full/118/1/309#otherarticles>

### Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):  
**Genetics & Dysmorphology**  
[http://www.pediatrics.org/cgi/collection/genetics\\_and\\_dysmorphology](http://www.pediatrics.org/cgi/collection/genetics_and_dysmorphology)

### Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
<http://www.pediatrics.org/misc/Permissions.shtml>

### Reprints

Information about ordering reprints can be found online:  
<http://www.pediatrics.org/misc/reprints.shtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

